Antibodies News and Research

RSS

Spike antibody durability in mRNA vaccinated individuals with or without prior SARS-CoV-2 infection

A new study examined SARS-CoV-2 spike IgG antibodies in a longitudinal cohort, comparing antibody durability in individuals who received an mRNA SARS-CoV-2 vaccine with or without prior SARS-CoV-2 infection.

3 Nov 2021

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Researchers sought to analyze immune responses after homologous vaccinations or after heterologous Vector/mRNA vaccinations, with respect to anti-COVID-19 immune responses and the development of autoantibodies.

3 Nov 2021

Antibody response of COVID-19 patients to SARS-CoV-2 and seasonal coronaviruses

Scientists conducted a cohort study and measured the prevalence and the levels of antibody responses to the nucleocapsid protein of SARS-CoV-2 and four seasonal human coronaviruses.

3 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

Fetal heart rate monitoring is feasible, accurate for managing high-risk pregnancies

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that heart rate monitoring is a feasible, accurate tool to check for heart rhythm abnormalities in the fetuses of pregnant women with anti-Ro/SSA antibodies.

2 Nov 2021

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.

2 Nov 2021

Scientists discover key component of cellular malfunction that contributes to growth of tumors

Scientists have homed in on a crucial step within the sequence of chemical reactions that govern regulation of cell division, proliferation and death, and whose malfunction contributes to the growth of tumors.

2 Nov 2021

Black patients with systemic sclerosis may experience poorer outcomes more often than others

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups, and these worrying disparities may be driven by several socioeconomic factors.

2 Nov 2021

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

An overview of the PIENTER-Corona (PiCo) study, which is a Dutch nationwide efficacy comparison study on four different COVID-19 vaccines.

2 Nov 2021

IBD patients produce a strong antibody response to COVID-19 vaccination, finds study

Researchers at Cedars-Sinai found that patients with inflammatory bowel disease (IBD)─whose treatment can weaken the immune system─produced a strong antibody response to COVID-19 vaccination.

2 Nov 2021

The pros and cons of a COVID-19 vaccine booster

The authors provide an overview of current literature available to assess the need for COVID-19 vaccine booster doses and their potential target population.

2 Nov 2021

End-stage renal disease negatively impacts COVID-19 vaccine response

Researchers perform a systematic review of people with end-stage kidney disease receiving SARS-CoV-2 vaccines to assess their immunogenicity rates.

2 Nov 2021

Research collaboration identifies antibody that limits the severity of coronavirus infections

A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.

2 Nov 2021

The impacts of the SARS-CoV-2 pandemic on digestive health

The UEG Public Affairs Committee has published a position paper to educate policymakers, patients, healthcare professionals, and the general public about the impacts of the COVID-19 pandemic on digestive health.

2 Nov 2021

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

A recent study has evaluated vaccine-induced humoral and cellular immunity against SARS-CoV-2 six months post BNT162b2 (Pfizer-BioNTech) vaccination.

2 Nov 2021

Trends in SARS-CoV-2 seroprevalence in Massachusetts

A new study reported findings from a retrospective, de-identified and systematic survey of SARS-CoV-2 seroprevalence among childbearing women in Massachusetts.

2 Nov 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

Identification of common genes in COVID-19 and COPD

Based on protein-protein interactions, the paper shows the presence of ten genes that overlap between the two illnesses, also shared by several other deadly and debilitating diseases.

2 Nov 2021

Placental cell-type productively infected with SARS-CoV-2

A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.

2 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Antibodies News and Research

Spike antibody durability in mRNA vaccinated individuals with or without prior SARS-CoV-2 infection

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Antibody response of COVID-19 patients to SARS-CoV-2 and seasonal coronaviruses

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

Fetal heart rate monitoring is feasible, accurate for managing high-risk pregnancies

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

Scientists discover key component of cellular malfunction that contributes to growth of tumors

Black patients with systemic sclerosis may experience poorer outcomes more often than others

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

IBD patients produce a strong antibody response to COVID-19 vaccination, finds study

The pros and cons of a COVID-19 vaccine booster

End-stage renal disease negatively impacts COVID-19 vaccine response

Research collaboration identifies antibody that limits the severity of coronavirus infections

The impacts of the SARS-CoV-2 pandemic on digestive health

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

Trends in SARS-CoV-2 seroprevalence in Massachusetts

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

Identification of common genes in COVID-19 and COPD

Placental cell-type productively infected with SARS-CoV-2

SARS-CoV-2 variants neutralized by camel nanobodies

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News